Thyroid Cancer

After rising over a 35-year period, thyroid cancer incidence in the U.S. plateaued from 2010 to 2019, according to findings published in The Lancet Diabetes & Endocrinology.

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based therapies and lead to significant weight loss in adults, according to top-line results from a phase 1b/2a trial.

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP-1 initiation, researchers reported.

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, including measuring body fat to diagnose obesity instead of BMI alone.

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid.

Adults with low-risk thyroid cancer who underwent surgery had significant reductions in cancer-related fear and worry after their procedure compared with before surgery, researchers reported.

Suicide rates for individuals diagnosed with cancer increased over the past 2 decades, according to results of a retrospective study.

Patients with primary thyroid cancer who received radioactive iodine exhibited increased risk for melanoma and other nonkeratinocyte skin cancers, according to study results.

Adults diagnosed with endogenous Cushing’s syndrome have a higher risk for developing cancer compared with controls without the condition, according to data published in the European Journal of Endocrinology.

An AI model achieved higher accuracy than three cytopathologists for determining malignancy in a large dataset of image patches of thyroid fine-needle aspiration whole-slide images, according to a study published in Thyroid.